Recent advancements in anti-obesity drugs have transformed the market, making them the most impactful trend for the next 12 ...
Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are ...
Novo Nordisk, maker of the blockbuster drugs for diabetes and weight loss respectively, has a market capitalisation of ...
The drugs belong to a class of treatments known as GLP-1s, which help regulate blood sugar and cause the stomach to empty ...
The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs analysts said in a r… ...
Telehealth company Hims & Hers announced they will begin selling off-brand GLP-1 drugs similar to Ozempic and Wegovy at a ...
Providing GLP-1 drugs to 19.7 million Medicare beneficiaries with obesity would cost $268 billion a year, researchers ...
New Delhi: At 17, Israel McKenzie was so burdened by obesity that he stopped going to high school in person and was ...
Taipei, Taiwan – Ozempic is big business in China. Last year, the Danish pharmaceutical giant Novo Nordisk doubled its sales ...
While the UK stock market is rising, the Diageo share price is falling. Here, Edward Sheldon looks at what’s going on with ...
Giving obese children semaglutide could reduce their risk by 90 per cent. It comes after Diabetes UK revealed obesity has ...
There is no doubt that beauty culture penetrates all aspects of contemporary society. According to a Mckinsey & Company ...